Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
Key Points Shares of Gilead Sciences (NASDAQ: GILD) have lagged the S&P 500 average this year, rising only 9% despite…
The Archive
Author: admin
A Smarter Alternative to the Vanguard S&P 500 ETF for Risk-Aware Investors
Key Points In the stock market, many things are true, and new investors can and do learn at least two…
If I Could Tell Every Dividend Investor 1 Thing About Building Passive Income in 2026, It’s This
Key Points When choosing dividend stocks or ETFs, it’s important to look beyond just the yield figure. Ultimately, total returns…
This Possible Social Security “Fix” Would Act as an Indirect Benefit Cut to Millions of Americans
Key Points If you’re counting on Social Security to cover a large share of your retirement expenses, the thought of…
Dollar General offers retro prices
Dollar General has seen growth in a key customer area, driven by the challenging economy. Citigroup analyst Paul Lejuez asked…
Google’s In-House AI Chip Strategy Could Be a Bigger Threat to Nvidia Than Investors Think. Here’s Why.
Key Points Google could lower its AI compute costs by up to 30% using its own processors. The company is…